Overview
- The president announced a three-step tariff timetable that starts with zero percent imports for two years, rises to 100 percent for one year and then to 200 percent thereafter, a plan unveiled in public posts this week that gives manufacturers a limited window to onshore production.
- The administration frames the policy as a reshoring tool to push drugmakers to build US plants, but industry leaders say generics operate on thin margins and cannot quickly absorb steep import levies without raising prices or exiting the market.
- India is singled out as particularly exposed because it supplies a large share of US generics by volume and exported roughly $9–10 billion in pharmaceuticals to the United States in 2025, which could put many commonly used medicines at risk of higher cost or reduced supply.
- Supply-chain limits worsen the challenge because many active pharmaceutical ingredients are sourced from China, building new US manufacturing capacity would be slow and costly, and companies warn the plan could trigger drug shortages or higher out-of-pocket costs for patients.
- Key details remain unresolved and will shape outcomes: whether the administration grants carve-outs, how tariffs would be enforced, pending legal and trade challenges, and whether negotiations with India or industry deals will alter the timetable.